WEALTH UNIVERSITY

[$heff]

AEMD (.515) is looking forward to presenting their data from India w/ Dr. Kher presenting. This data will allow the company to do clinical studies in the U.S. and will help faciliate potential partnerships w/ big pharma. The American Society of Nephrology meeting this Friday will be huge for AEMD. They will then be able to meet with the FDA to discuss their clinical results and get the stamp of approval to be used as an adjunct therapy to first-line therapy for HCV. Win-win situation for the company. $heff